focus -WSS

focus

author：fashion 2025-09-05 07:00:25 - browse：1

Exact Sciences headquarters. -- biotech coverage from STAT — Exact Sciences' headquarters in Madison, Wis. Wikimedia Commons

Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue.

That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading on Wednesday, shortly after Exact released its financial updates, shares tumbled as low as $47.24.

The seemingly paradoxical result reflects worries about a potential slowdown in future growth at Exact, a $10 billion biotech best known for Cologuard, a colon cancer screening test that detects blood and DNA from stool samples. The test, which first won regulatory approval in 2014, was designed to boost cancer screening rates by providing a more convenient alternative to colonoscopies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： FDA advisory panel to debate high blood pressure devices

focus

WSS

Can U.S. cancer drug shortages be fixed?

CDC says it’s too soon to assess risk posed by Covid subvariant

Study: Pain burden is higher in Black NFL players than white ones

Listen: Vivek Ramaswamy's star turn & leaky drug data

Iowa House, Senate pass 6

Living with Fabry disease, a condition that causes chronic pain

explore

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Kellogg’s is going to war over Mexico’s nutrition label rules

How to save PrEP access — and even expand it

Study: Pain burden is higher in Black NFL players than white ones

Medical records are filled with copy

FDA greenlights medical device to combat bladder issues

At least 13 dead in Texas as scorching temps continue

Meadows told special counsel he could not recall Trump ever declassifying Mar

Hepatitis C has a cure — but many Americans still lack access to it

Listen: Vivek Ramaswamy's star turn & leaky drug data

hotspot

FDA greenlights medical device to combat bladder issues

CDC says it’s too soon to assess risk posed by Covid subvariant

Intellia plays down concerns on accidental germline transmission

CDC says it’s too soon to assess risk posed by Covid subvariant

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

DeSantis wants to import drugs. Biden’s FDA blasted his plan

knowledge

focus

Wikipedia

leisure time